Valneva Reports Strong Four-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ

Valneva SE (VALN) announced positive four-year antibody persistence data for its single-dose chikungunya vaccine, IXCHIQ, demonstrating robust and long-lasting immune responses. The study showed 95% of healthy adults maintained neutralizing antibody titers above the seroresponse threshold, with comparable persistence and safety profiles observed across all age groups, including older adults, reinforcing the vaccine's long-term efficacy and safety.

Analysis

Valneva SE (VALN) has reported highly positive four-year antibody persistence data for its single-dose chikungunya vaccine, IXCHIQ. The results demonstrate significant long-term immunogenicity, with 95% of healthy adult participants maintaining neutralizing antibody titers above the seroresponse threshold four years after vaccination. Crucially, the data shows comparable antibody persistence and seroresponse rates between younger (18-64 years) and older (65+) adults, a key factor that supports the vaccine's utility across all age groups and potentially broadens its addressable market. The long-term safety profile is also reinforced, with no new safety concerns or adverse events of special interest identified over the follow-up period. The commitment to a ten-year follow-up study provides a clear path to generating further data that could solidify IXCHIQ's position as a durable, single-dose solution, strengthening its commercial and competitive profile.

Key Decisions for Investors

• The four-year data significantly de-risks the long-term value of IXCHIQ, and investors should consider this a material positive for Valneva's future revenue stream from this asset.
• The strong and comparable efficacy in older adults is a key commercial advantage that may accelerate market adoption and should be factored into models for peak sales potential.
• Monitor for future data readouts from the ongoing ten-year study, as continued positive results will serve as further catalysts to reinforce the vaccine's best-in-class potential for long-term protection.